Center Variation in Intention‐to‐Treat Survival Among Patients Listed for Liver Transplant

Allison J. Kwong, Avegail Flores, Giovanna Saracino, Jodi Boutté, Greg McKenna, Giuliano Testa, Ranjeeta Bahirwani, Anji Wall, W. Ray Kim, Göran Klintmalm, James F. Trotter, Sumeet K. Asrani – 29 July 2020 – In the United States, centers performing liver transplant (LT) are primarily evaluated by patient survival within 1 year after LT, but tight clustering of outcomes allows only a narrow window for evaluation of center variation for quality improvement. Alternate measures more relevant to patients and the transplant community are needed.

Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice

Anja Christina Koop, Nina Doreen Thiele, David Steins, Erik Michaëlsson, Malte Wehmeyer, Ludger Scheja, Babett Steglich, Samuel Huber, Julian Schulze zur Wiesch, Ansgar W. Lohse, Jörg Heeren, Johannes Kluwe – 29 July 2020 – Myeloperoxidase (MPO) activity has been associated with the metabolic syndrome, cardiovascular and liver disease. Here, we evaluate the therapeutic potential of MPO inhibition on nonalcoholic steatohepatitis (NASH) and NASH‐induced fibrosis, the main determinant of outcomes.

The Selective Peroxisome Proliferator‐Activated Receptor Gamma Modulator CHS‐131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis

Nikolaos Perakakis, Aditya Joshi, Natia Peradze, Konstantinos Stefanakis, Georgia Li, Michael Feigh, Sanne Skovgard Veidal, Glenn Rosen, Michael Fleming, Christos S. Mantzoros – 28 July 2020 – CHS‐131 is a selective peroxisome proliferator‐activated receptor gamma modulator with antidiabetic effects and less fluid retention and weight gain compared to thiazolidinediones in phase II clinical trials. We investigated the effects of CHS‐131 on metabolic parameters and liver histopathology in a diet‐induced obese (DIO) and biopsy‐confirmed mouse model of nonalcoholic steatohepatitis (NASH).

Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression

Yong Chun Chong, Tan Boon Toh, Zhiling Chan, Quy Xiao Xuan Lin, Dexter Kai Hao Thng, Lissa Hooi, Zhaobing Ding, Timothy Shuen, Han Chong Toh, Yock Young Dan, Glenn Kunnath Bonney, Lei Zhou, Pierce Chow, Yulan Wang, Touati Benoukraf, Edward Kai‐Hua Chow, Weiping Han – 27 July 2020 – Tumor‐specific metabolic rewiring, acquired to confer a proliferative and survival advantage over nontransformed cells, represents a renewed focus in cancer therapy development.

Subscribe to